Four-Week Safety and Efficacy Study of Dorzolamide, a Novel, Active Topical Carbonic Anhydrase Inhibitor

Day²,

et al. 2004

Eye

Purpose To compare ocular tolerability of dorzolamide 2%, brinzolamide 1%, and placebo given three times daily. Methods A prospective, double-masked, three-centre, crossover comparison in which 25 ocular hypertensive or primary-open angle glaucoma subjects were randomized to receive dorzolamide, brinzolamide, or placebo three times daily for 3 days. Intraocular pressure, visual acuity, a visual analogue scale, and ocular and systemic symptom queries were completed at the end of each period.

Section: Introductionmentioning

confidence: 99%

Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects

Day²,

et al. 2004

Eye

“…[2] Due to the introduction of newer agents for the treatment of POAG and thereby reducing IOP, controlled clinical trials are required for the assessment of relative efficacy and safety of antiglaucoma agents. [3] Dorzolamide 2% (topical carbonic anhydrase inhibitor) is instilled three times a day thereby causing sustained reduction of the intraocular pressure (IOP) due to reduction in the flow of aqueous humor. [4] Latanoprost 0.005% (prostaglandin analogue), a potent ocular hypotensive agent is instilled once daily and its results in the reduction of IOP is almost comparable to Timolol.…”

Section: Introductionmentioning

confidence: 99%

A Prospective Comparative Study of Efficacy of Topical Anti – Glaucoma Drugs in Primary Open Angle Glaucoma

Abrar¹,

Rastogi²,

Ansari³

2017

AIMDR

Background: Glaucoma is an ischemic optic neuropathy comprising of raised intraocular pressure, optic disc changes and visual field defects. Due to fear of loss of vision, the therapy of Primary Open Angle Glaucoma (POAG) targets lowering the IOP by either medical or surgical means. The aim of the study is to compare the reducing efficacy of IOP using Dorzolamide and Latanoprost topical eye drops in patients with Primary open angle glaucoma. Methods: The study was conducted in the Department of Ophthalmology, Teerthankar Mahaveer Medical College, TMU, Moradabad. Sixty patients were recruited for the study and divided into two groups of 30 each. Group D were administered with Dorzolamide 2% eye drops thrice daily while Group L received Latanoprost 0.005%eye drops once daily. Results: Out of all sixty patients, 56.67% belong to 41-60 years of age group. 28.33% of the patients were of more than 61 years of age and only 9 patients i.e. 15% were of between 20-40 year of age. The mean baseline IOP in Group D was 26.60 ± 2.91 mmHg and in Group L was 26.82 ± 2.23 mmHg (P=0.22). The mean IOP gradually decreases until 12th week in both the groups and the results were comparable in between the groups. The percent change in IOP in Group D was 29.97% and in Group L was 38.82%. Conclusion: Although both (latanoprost and dorzolamide) drugs were well tolerated by all the patients but the efficacy in decreasing IOP is superior with latanoprost.

“…For example, Wilkerson et al (6) observed that corneal thickness (CT) increased in a group using dorzolamide, while other study did not show differences in CT between users and non-users of dorzolamide (4). However, Konowal et al (7) described 9 cases of irreversible corneal decompensation after the use of dorzolamide.…”

mentioning

confidence: 99%

“…Therefore, there was no physiological effect of ocular dorzolamide, except on the eye itself (2). The increase in the thickness of the human cornea with the use of topical dorzolamide was only reported in abnormal situations such as glaucoma (6,17), ocular hypertension (6) and penetrating keratoplasties (7). It is possible that, under these conditions, the cornea treated with a carbonic anhydrase inhibitor could totally or partially lose the capacity to use its compensatory mechanisms.…”

mentioning

confidence: 99%

<a name="home"></a>Effect of topical dorzolamide on rabbit central corneal thickness

Almeida

Souza

2006

Braz J Med Biol Res

Our objective was to study the effect of dorzolamide on corneal hydration in an 18-week controlled experiment using ultrasonic pachymetry. Twenty-eight male rabbits were divided randomly into four groups. The 7 rabbits in each group received eye drops containing either 2% (w/v) dorzolamide or placebo in their right eye, or in their left eye. The 2% dorzolamide rabbits were treated every 8 h. Fellow eyes are defined as eyes which did not receive either dorzolamide or placebo. The study was blind for both the person who applied the drug and the one who performed the pachymetry. The effect of treatments is reported on the basis of the percentage of pachymetric variation compared to the measurement made before drug application. There was no significant difference (P = 0.061) in pachymetric variation between dorzolamide (-4.42 ± 11.71%) and placebo (2.48 ± 9.63%). However, there was a significant difference (P = 0.0034) in pachymetric variation between the dorzolamide fellow eyes (-7.56 ± 10.50%) and the placebo (-4.42 ± 11.71%). In conclusion, dorzolamide did not increase the corneal thickness in rabbits.